Compare IRON & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | ASH |
|---|---|---|
| Founded | 2017 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2020 | 2016 |
| Metric | IRON | ASH |
|---|---|---|
| Price | $74.14 | $68.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $103.18 | $65.57 |
| AVG Volume (30 Days) | 560.7K | ★ 583.0K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.38% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | ★ $1,824,000,000.00 |
| Revenue This Year | N/A | $2.58 |
| Revenue Next Year | $283.52 | $4.28 |
| P/E Ratio | ★ N/A | $829.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.00 | $46.30 |
| 52 Week High | $99.50 | $69.66 |
| Indicator | IRON | ASH |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 60.05 |
| Support Level | $70.29 | $62.47 |
| Resistance Level | $82.65 | N/A |
| Average True Range (ATR) | 3.37 | 1.78 |
| MACD | -0.51 | -0.25 |
| Stochastic Oscillator | 19.25 | 80.57 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.